EKF Diagnostics Holdings plc

EKF reported H1 2025 revenue of GBP 25.2 million, roughly flat versus the prior year, with constant-currency revenue closer to GBP 26 million. Gross margin improved to 50% from 48%, EBITDA rose 7.4% to GBP 5.8 million versus GBP 5.4 million, and profit increased 16.1%. Cash was GBP 16.6 million at period end, and management said it remains on target to reach about GBP 20 million by year-end. For the full year, management said revenue looks to be in line with expectations, while EBITDA is helped and hindered by a lot of low-margin analyzer build in H1; they did not give a precise EBITDA guide. CapEx in 2025 is expected to be around GBP 2.5 million for Point-of-Care, GBP 1 million for the German facility, and about GBP 1 million in the U.S., with another GBP 3.5 million to GBP 4 million likely in 2026, mainly for Point-of-Care capacity. The share buyback has already repurchased 4.6 million shares and is intended to continue indefinitely.

Gavin Jones framed the quarter as a strategy execution update, emphasizing that the business has been realigned toward higher-margin Point-of-Care, hematology and BHB products. He highlighted 60% growth in hematology analyzer production, 12% BHB growth, and new contracts in Africa and Latin America as evidence that the strategy is taking hold. His tone was upbeat but cautious on timing, especially around Life Sciences ROI, where he stressed this is a long-term investment and said the company does not want to overpromise.

Stephen Young focused on capital spending and its limited short-term margin impact. He said 2025 CapEx is mainly Point-of-Care, with about GBP 2.5 million for Point-of-Care, GBP 2.5 million for the German facility, and about GBP 1 million in the U.S., while 2026 could see another GBP 3.5 million to GBP 4 million, again mostly for Point-of-Care capacity; he said this should not have a major short-term margin effect. He also said the Fermentation CapEx is done in the U.S., and management expects the analyzer and consumables capacity work to continue into 2026 and beyond.

Analysts asked whether the strong analyzer build meant consumables were down; management said no, noting analyzer placements come with consumables and that consumable pull-through typically follows after 3 to 4 months, especially under 2- to 3-year tenders. Questions on the South Peru Life Sciences site focused on ROI and utilization; management said the site was needed to protect and serve the BHB business, estimated the investment at roughly GBP 5 million to GBP 7 million, and said utilization is still only around 10% to 15% but is rising. On the buyback, management said it is intended to be continuous and could be embedded as an ongoing policy, while on M&A they said EKF could be a consolidator or a target if the right opportunity came along.